Stock VIRX VIRACTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Delayed Nasdaq
Other stock markets
 16:27:22 15/05/2024 BST 		5-day change 1st Jan Change
0.82 USD +1.99% Intraday chart for Viracta Therapeutics, Inc. -0.12% +43.86%
05-14 Viracta Therapeutics Appoints Michael Faerm CFO MT
05-14 Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
AQ
Sunesis: Q1 Earnings Snapshot
AQ
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
AQ
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma
AQ
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
AQ
Viracta Therapeutics : HST 2024 – Presentation
PU
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
AQ
Sunesis: Q4 Earnings Snapshot
AQ
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
AQ
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
AQ
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
AQ
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
AQ
Sunesis: Q3 Earnings Snapshot
AQ
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Viracta Therapeutics to Present at Upcoming Investor Conferences
AQ
Viracta Therapeutics : R&D Day Presentation
PU
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIRX Stock
  4. News Viracta Therapeutics, Inc.
  5. Press Releases